Restoration of Normal Prothrombin Time/ International Normalized Ratio With Fresh Frozen Plasma in Hypocoagulable Patients
|
|
- Lester Higgins
- 6 years ago
- Views:
Transcription
1 Original Article Restoration of Normal Prothrombin Time/ International Normalized Ratio With Fresh Frozen Plasma in Hypocoagulable Patients Clinical and Applied Thrombosis/Hemostasis 2016, Vol. 22(1) ª The Author(s) 2014 Reprints and permission: sagepub.com/journalspermissions.nav DOI: / cat.sagepub.com Arthur J. Only Jr, BS 1, Phillip J. DeChristopher, MD, PhD 1, Omer Iqal, MD 1, and Jawed Fareed, PhD 1 Abstract Fresh frozen plasma (FFP) is an effective reversal agent for hypocoagulable patients. Its proven efficacy continues to prompt its usage as both a prophylactic and a therapeutic therapy. Although published guidelines encouraging the appropriate administration of FFP exist, overutilization continues. The purpose of these ex vivo studies was to determine the effects of succeeding volumes of FFP supplementation on hypocoagulable plasma prothrombin time/international normalized ratio (PT/INR). By analyzing the decline in PT/INR with varying volumes of FFP, a minimal required volume of FFP could be identified representing the optimal volume to administer while still providing therapeutic effect. A total of 497 plasma samples were screened for elevated PT/INR values and 50 samples were selected for inclusion in this experiment. The initial PTs/INRs ranged from 12.5 to 43.4 seconds/1.42 to Subsequent declines in PT/INR values were analyzed following addition of 50, 100, and 150 ml of FFP to a fixed volume of 250 ml of plasma ( seconds/ , seconds/ , seconds/ , and seconds/ , respectively). A nonlinear relationship between decline in INR values and percentage of FFP supplementation was demonstrated. The greatest effect on INR was obtained after supplementation with 50 ml (49%). Doubling and tripling the volume of FFP lead to significantly lower declines in INR (16% and 8%, respectively). Analysis of variance indicated a statistical significance with subsequent volume supplementation of FFP, but marginal clinical benefits exist between the PTs/INRs obtainable with increased FFP volume administration. Keywords fresh frozen plasma, hypocoagulable, prothrombin time, international normalized ratio Introduction Hemostasis could be defined as a physiologic equilibrium between coagulation and fibrinolysis. Blood remains in a hemodynamically fluid and inert state unless the coagulation cascade is activated. Virchow first described a triad of factors responsible for disruption of hemostasis leading to thrombosis. 1 Virchow triad describes the 3 primary factors that influence hemodynamics, stasis, endothelial damage, and hypocoagulable states. 1 Primary hemostasis consists of platelet adhesion, aggregation, and activation on the exposed subendothelial collagen following a vascular injury resulting in the formation of a primary hemostatic plug following vascular damage. 1 Secondary hemostasis involves interaction of coagulation factors related to extrinsic and intrinsic coagulation pathways culminating in the deposition of insoluble fibrin, which is further stabilized by crosslinking of the initial fibrin clot. 1 Coagulopathy follows an imbalance between activation of coagulation and compromised inhibition of coagulation and fibrinolysis. 2 Anticoagulant drugs are used to prevent and manage thrombotic disorders and their complications such as stroke. 3,4 Warfarin is the most commonly prescribed oral anticoagulant in the United States for patients with hypercoagulable conditions 5 although a number of other non-vitamin K antagonists medications are licensed in the United States. In the United States as reported by the National Collection and Utilization Survey, approximately 5,700,000 units of plasma were manufactured for transfusion in An estimated 3 million units of fresh frozen plasma (FFP) are administered annually in the United States 6 often to critically ill patients with coagulopathies. Prophylactic FFP is often administered prior to invasive procedures to hemodynamically unstable patients with elevated prothrombin time/international normalized ratio (PT/INR), despite lack of adequate supportive 1 Department of Pathology, Loyola University Chicago, Maywood, IL, USA Corresponding Author: Jawed Fareed, Loyola University Chicago, 2160 First Ave, Maywood, IL 60153, USA. jfareed@luc.edu
2 86 Clinical and Applied Thrombosis/Hemostasis 22(1) INR evidence. 7 Most consensus guidelines mention only few clear indications for transfusion of FFP including treatment of bleeding due to multiple factor deficiency, emergency reversal of vitamin K antagonist, and treatment of thrombotic thrombocytopenic purpura (TTP), and other thrombotic microangiopathies. 8 Several published audits of FFP transfusion very often suggested inappropriate excess usage. 9 This excessive usage of FFP, besides incurring unnecessary health care expenditures, is actually etiologic in causing harm to patients due to complications such as transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO). 10 Reports on intensive care unit transfusion practices in Europe and United States indicate an estimated 33% of plasma is transfused to nonbleeding patients, despite lack of evidence of benefit. 6,11,12 INR Changes Post FFP Supplementation Figure 1. Baseline international normalized ratio (INR) of hypocoagulable patient samples (N ¼ 50). Hypocoagulable patients and the effects of fresh frozen plasma supplementation on the restoration of clotting profile. This unnecessary use of FFP not only incurs increased health care costs but also consumes considerable resources of blood components, which could either be appropriately used in patients who need them or whose manufacture could be avoided at the outset. Availability and implementation of clearly established transfusion guidelines, which are actually followed by physicians, are desperately needed to prevent such wastage. Based on this background it is hypothesized that the maximum effect on restoration of hemostasis is most apparent after administration of the equivalent of 2 units of FFP in patients with initial PT/INRs above 20 seconds/2.0. In order to evaluate this hypothesis, this ex vivo study was conducted to analyze the effective restoration of normal PT/INR times to hypocoagulable plasma samples after supplementation of 3 varying quantities of FFP. Fresh frozen plasma is a blood component obtained from the centrifugal separation of the fluid component of anticoagulated whole blood, 13 then frozen within 8 hours to at least 18 C. A unit of FFP has a volume of 175 to 250 ml and an inherent INR of up to This solution contains the essential PT(sec) PT Changes Post FFP Supplementation Figure 2. Baseline prothrombin time (PT) of hypocoagulable patient samples (N ¼ 50). Hypocoagulable patients and the effects of fresh frozen plasma supplementation on the restoration of clotting profile. coagulation factors, which upon activation promote fibrin clot formation. The FFP consist of vitamin K-dependent factors II, VII, IX, and X, factors V and VIII, fibrinogen, and fibrinolytic/complement factors, which are among the soluble coagulation factors The FFP is routinely used in the United States for therapeutic reversal of anticoagulation or to stop bleeding in actively hemorrhaging patients, despite scarce evidence from randomized controlled trials to support its use. 16 The FFP is easily produced and relatively inexpensive. Its primary drawbacks include the potential risk of transfusion-transmitted infections, allergic reactions, TRALI, and TACO. In emergency situations, FFP may require significant time to obtain from a regional blood bank and more time to thaw in the Transfusion Service. Furthermore, it may require several hours after administration in order to establish full physiologic anticoagulation reversal. 17,18 Current clinical practices promote excessive usage of FFP, which may result in complications that are better prevented. 19 Ideally, such an excessive volume of FFP may not be necessary for effective anticoagulant reversal. In light of the lack of proper guidelines, this ex vivo study was designed to determine the minimal required volume of FFP necessary to restore normal clotting times (PT/INR) in patients with altered vitamin K-dependent coagulation factors due to warfarin therapy or altered hepatic function. Materials and Methods Deidentified and discarded blood samples were collected from the Loyola University Health System/Trinity Core Clinical Laboratory under an approved IRB protocol. Samples were randomly selected based on observation of icteric plasma. Icteric plasma was taken as an indicator of plasma with strong likelihood of elevated PTs. A total of 497 samples were screened for elevated PT/INRs using Innovin (Dade) on the Automated Coagulation Laboratory 300 Plus (ACL300 Plus,
3 Only et al 87 Instrumentation Laboratory). A total of 50 samples were selected for this experiment from the original 497 cohort. Selection criteria for inclusion into this study were based on an initial PT/INR of 12/1.4. The 50 samples PT/INR ranged between 12.5 and 43.4 seconds/1.42 and A laboratory reference PT time of 9 seconds represented the experimental control value. The FFP used in this experiment was manufactured in the laboratory by a method, which is equivalent to Blood Center manufacturing steps of licensed FFP. Blood draws from 10 males and 10 females (apparently healthy) were obtained. The blood was then centrifuged after the supplementation of sodium citrate (1part of citrate to 9 parts of blood) at 3000 rpm to obtain platelet poor plasma (PPP). Then, all of the plasma was pooled, mixed, and then aliquoted in 10-mL tubes. All aliquots were then stored at 70 C until used. Sample Preparation The following protocol was executed for each of the 50 specimens. From each specimen, 250 ml of plasma was placed into 4 vials individually labeled A, B, C, and D. Vial A was supplemented with 50 ml of saline, vial B was supplemented with 50 ml of FFP, vial C was supplemented with 100 ml of FFP, and vial D was supplemented with 150 ml of FFP, respectively. Saline- and FFP-supplemented vials were analyzed using the ACL300 Plus instrument to determine PT values. In the design of this in vitro experiment, it is assumed that based on the 5-L blood volume of a patient averaging 70 kg in weight, the approximate plasma obtained based on the normal 45% hematocrit is 2.75 L. Considering administration of 2 bags (500 ml) to such a patient, the new circulating volume of plasma in that patient would be 3.25 L. We have designed this in ex vivo experiments, where we placed 50, 100, and 150 mlof FFPin a fixed volume of 250 ml of plasma and then determined the PT/INR values. The percentage of FFP administered was 16.6% when 50 ml of FFP supplemented; 28.6% when 100 ml of FFP was supplemented; and 37.5% when 150 ml of FFP was supplemented. The thought behind this approach was to identify the minimal volume of FFP necessary to correct PT/INR to avoid complications of circulatory overload while still adequately restoring hemostasis. All PT values for the discarded blood samples included in this study were obtained within 4 hours of their collection from the laboratory. The results are tabulated and graphed. Statistical analysis was performed using Sigmaplot 12.0 statistical programing software. Means and standard deviations of all parameters were calculated for all values. The INRs based on PT values were calculated using a laboratory reference PT of 9 seconds and the International Sensitivity Index (ISI) value of 1.02 for Innovin. Optimal ISI reagents are standardized in clinical laboratories in order not to influence the PT/INR values. After all samples have been analyzed, all data were incorporated into a composite to generate composite means for each supplement group. One-way repeated measure analysis of variance (ANOVA) statistical testing was then performed using Graph Pad Prism. All Table 1. Comparison of the International Normalized Ratio (INR) Values of Native Hypocoagulable Patient Plasma Samples With Saline Supplementation and Fresh Frozen Plasma (FFP)-Corrected Groups. a INR Mean St Dev Initial ml saline ml FFP ml FFP ml FFP Abbreviations: PT, prothrombin time; St Dev, standard deviation. a Saline supplementation of the different samples resulted in a slight elevation in PT values. FFP supplementation at varying volumes resulted in marked reduction in the INR values. Table 2. Comparison of the PT Values of Native Hypocoagulable Patient Plasma Samples With Saline Supplementation and Fresh Frozen Plasma (FFP)-Corrected Groups. a PT Mean St Dev Initial ml Saline ml FFP ml FFP ml FFP Abbreviations: PT, prothrombin time; St Dev, standard deviation. a Saline supplementation of the different samples resulted in a slight elevation in PT values. FFP supplementation at varying volumes resulted in marked reduction in the PT values. pairwise multiple comparison procedures were conducted using Student-Newman-Keuls method. The level of statistical significance was established using a P value of <.001. Results Analysis of the 50 plasma samples revealed that the initial PT/ INR ranged from 12.5 to 43.4 seconds/1.42 to The composite initial mean PT/INR for the 50 icteric plasma samples used was seconds/ In analysis of each plasma sample, a combination of 50 mlofsaline,50ml of FFP, 100 ml offfp,150ml of FFP placed in vials A, B, C, and D, respectively, with a fixed volume of 250 ml of icteric plasma in each vial, the PT/INR values obtained were seconds/ , seconds/ , seconds/ , and seconds/ , respectively (Tables 1 and 2) (Figures 1 and 2). Fixed volumes in this ex vivo experimental model identified a negative correlation between percentage of FFP supplementation and change in INR. With increasing volumes of FFP supplementation, there was a corresponding decrease in the INR. Following 50 ml of FFP supplementation (representing a 16.6% supplementation), there was a drop in INR from an initial 2.99 to With the supplementation of 100 and 150 ml of FFP, the INR dropped to 1.27 and to The addition of 100 and 150 ml of FFP represent 28.6% and 37.5% supplementation of FFP to the original 250 ml volume, respectively
4 88 Clinical and Applied Thrombosis/Hemostasis 22(1) Composite Mean INR Table 1: INR INR % FFP supplementation 0.00 Figure 3. Evaluation of the correlation between percentage of fresh frozen plasma (FFP) supplementation to a set volume of plasma and the corresponding reduction in international normalized ratio (INR) values. (Figure 3). The varying volume supplementation in this experiment would correspond to volumes of 550 ml, 1.1 L, and 1.65 L FFP supplementation in a 70-kg adult. The corresponding decline in INR with each sequential increase in percentage of supplementation of FFP was 49%, 16%, and8%. The decline in PT/INR with subsequent volumes of FFP is nonlinear. Discussion Fresh frozen plasma represents one of the various therapeutic options available for the correction of anticoagulable states and treatment of hemorrhages. Its composition of essential clotting factors and proteins necessary for the activation of the intrinsic/ extrinsic pathways of the coagulation cascade make it a useful blood component for manipulation of a patient s coagulation profile. This experiment was designed considering a possible clinical scenario. Many patients present to emergency departments daily in hypocoagulable states, which are also highly prevalent in critically ill patient populations. Actively bleeding patients require immediate intervention. While conducting primary evaluations, routine blood draws are sent to the laboratory and patients are typically started on normal saline to maintain hemodynamic stability. Of the many preliminary laboratory tests requested, the coagulation profile is of particular importance when determining the most appropriate direction of treatment for correction of hypocoagulable states. Once the coagulation profile is available, it is evident whether the patient is anticoagulated/warfarinated based on elevations in PT time. The recommended therapeutic range for warfarin therapy is an INR between 2 and 3. The FFP is more commonly used initial option to correct elevated PT/INR in warfarinated or bleeding patients. However, the risk/benefit profile of FFP use, which has limitations and a very narrow therapeutic window, is not widely appreciated or considered by ordering physicians. Figure 4. Comparison of the international normalized ratio (INR) values of native hypocoagulable patient plasma samples with saline supplementation and fresh frozen plasma (FFP)-corrected groups. Saline supplementation of the different samples resulted in a slight elevation in INR values. FFP supplementation at varying volumes resulted in marked reduction in the INR values. PT(sec) Composite Mean PT recordings 13.3 Table Figure 5. Comparison of the PT values of native hypocoagulable patient plasma samples with saline supplementation and fresh frozen plasma (FFP)-corrected groups. Saline supplementation of the different samples resulted in a slight elevation in PT values. FFP supplementation at varying volumes resulted in marked reduction in the PT values. PT indicates prothrombin time. The use of warfarin depletes vitamin K-dependent coagulation factors that are necessary for the activation of the extrinsic coagulation pathway. Also, patients with liver pathology (liver insufficiency or end-stage failure) present with elevated PT/INR due to the liver s inability to generate vitamin K-dependent factors, especially factor VII. The lack of available essential clotting factors coupled with the increased total blood volume secondary to intravenous fluid supplementation further elevates the PT/INR in these hypocoagulable patients. The 50 ml of saline that was supplemented to the 250 ml of
5 Only et al 89 Table 3. ANOVA Statistical Analysis. Vial Group N Missing Median 25% 75% Stats on PT a - Initial A 50 ml saline B 50mL FFP C 100 ml FFP D 150 ml FFP Stats on INR a - Initial A 50 ml saline B 50mL FFP C 100 ml FFP D 150 ml FFP Comparison Diff of Ranks q P < ml saline vs 150 ml FFP Yes 50 ml saline vs 100 ml FFP Yes 50 ml saline vs 50 ml FFP Yes 50 ml saline vs initial Yes Initial vs 150 ml FFP Yes Initial vs 100 ml FFP Yes Initial vs 50 ml FFP Yes 50 ml FFP vs 150 ml FFP Yes 50 ml FFP vs 100 ml FFP Yes 100 ml FFP vs 150 ml FFP Yes Abbreviations: ANOVA, analysis of variance; FFP, fresh frozen plasma; INR, international normalized ratio; PT, prothrombin time. a Chi-square ¼ with 4 degrees of freedom (P <.001). patient plasma samples in our experiment is equivalent to the addition of 550 ml of normal saline to a 70-kg adult with an estimated plasma volume of 2.75 L. The effect of repleting lost volume to a bleeding patient causes a secondary dilutional effect on the PT/INR (Figures 4 and 5). Fresh frozen plasma contains all the key coagulation factors necessary to restore hemostasis. It is administrated as a colloid, and volume remains chiefly intravascular, expanding the patients total plasma volume. The effects of FFP as an anticoagulation reversal agent are volume dependent and time dependent. By increasing the quantity of FFP administrated, an INR goal is obtainable. The duration of FFP supplementation is limited by the individual half-lives of the coagulation factors that constitute the mixture. Factor VII in particular has the shortest half-life of 4 to 6 hours. A patient with iatrogenic or pathologic vitamin K deficiency needs continued vitamin K supplementation after the administration of FFP to sustain the reversal effects on hypocoagulability provided by FFP. An average healthy individual not on anticoagulation therapy has an approximate PT/INR of 11 to 14 seconds/0.9 to For patients anticoagulated with warfarin, for example, the target INR is in the range of 2 to 3. In this study, plasma samples within the range of normal-, therapeutic-, and supratherapeutic INR values were tested to identify the effects of supplementation with varying volumes of FFP on the INR. Current excessive usage of FFP suggests that PT/INR correction to a desired point depends upon volume, and it is assumed that a linear relationship exists between plasma dosage and PT/INR. In fact, Figure 3 illustrates a more negative exponential relationship between a decline in INR and an increase in volume supplementation, with the greatest effect on reversal of an elevated INR being obtained with the initial volume of FFP supplemented to a plasma volume with a therapeutic INR. The effects of this initial volume of 50 ml supplementation to 250 ml correlates with 550 ml of FFP supplementation to a 70-kg adult. The 1.51 INR obtained after this initial supplementation of FFP represents a 49% drop in INR. Doubling this volume only leads to a marginal 16% decline in INR. Tripling the initial FFP volume further drops the INR by 8%. With further FFP supplementation, the slope of the line continues to flatten. Although our ANOVA indicates statistical significance is present with additional FFP supplementation, marginal clinical benefits of further FFP supplementation are not likely once an INR of 1.5 has been achieved (Table 3). Current consensus guidelines also support that an INR of 1.5 is considered safe to perform a variety of invasive procedures, thus also negating the value of further FFP supplementation. 21 Hemostasis is a complex physiologic process. The construction of any experiment to modify any particular aspect of this complicated system has inherent limitations. All of the samples used in this experiment were obtained from a single institution thus potentially limiting the population variability. Our experiments only considered coagulation status. No consideration was taken into the status of platelet function or count, both of which might additionally increase risks of clinical bleeding. Also, the variable of time and timing of the dose was not investigated. Thus, the duration of elevated INR reversal using FFP
6 90 Clinical and Applied Thrombosis/Hemostasis 22(1) was not established. To analyze the overall reduction in risk of bleeding complications with FFP supplementation, these limitations, which have clinical importance, would need to be separately considered and tested. Conclusion The therapeutic benefits of FFP are experimentally and statistically evident for the reversal anticoagulation. Supplemental FFP s effects are volume dependent. Current clinical usage of FFP lacks unequivocal guidelines and thus excessive quantities are habitually administered to hypocoagulable/anticoagulated patients. This study illustrates that the greatest reduction in elevated PT/INR is obtained after supplementation with 550 ml of FFP to the average-sized adult who s initial INR is >2. Our results support that administration of an initial bolus of 2 units possibly followed by initiation of a third unit of FFP drip with monitoring provides substantial reverses of PT/INRs above 17.8 seconds/2 and appears to provide appropriate treatment while minimizing the excessive administration of this blood component. Two clinical trials, one called The TOPIC trial ( trials.gov website, NCT ) aimed at demonstrating that omitting prophylactic FFP transfusion in critical ill patients with coagulopathy is safe in terms of bleeding complications and another called EPICC Trial ( website, NCT ) studying the effect of prophylactic FFP use in actively bleeding patients have both been recently completed. The publication of the results of these trials are eagerly anticipated to establish an improved evidence base for use of FFP in hypocoagulable patients. Acknowledgments The authors gratefully acknowledge the encouragement and support of Dr Eva Woijck, chairperson department of pathology. We are also thankful to Dr Debra Hoppensteadt for her scientific advice and logistic input for these studies. The authors are thankful to Dr Gail Hecht, assistant dean for medical students research, and Ms Kate Peterson, program coordinator of the STAR program, for their support in the completion of these studies. Authors Note This study was carried out as part of the STAR program at the Stritch school of medicine. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. References 1. Chung I, Lip GY. Virchow s triad revisited blood constituents. J Pathophysiol Hamemost Thromb. 2004;33(5-6): Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. 2008; 111(10): Vigue B. Bench-to-bedside review: optimizing emergency reversal of vitamin K antagonists in severe haemorrhage from theory to practice. Crit Care. 2009;13(2): Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr; Global Orthopaedic Registry Investigators. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008; 24(1): Yang L, Stanworth S, Hopewell S, Doree C, Murphy M. Is freshfrozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion. 2012;52(8): Dzik W, Rao A. Why do physicians request fresh frozen plasma? [Letter to the Editor]. Transfusion. 2004;44(11): West K, Adamson C, Hoffman M. Prophylactic correction of the international normalized ratio in neurosurgery: a brief review of a brief literature. J Neurosurg. 2011;114(1): Committee report: practice guidelines for blood component therapy. A report by the American Society of Anesthesiologists task force on blood component therapy. Anesthesiology. 1996;84(3): Metz J, McGrath KM, Copperchini MI, et al. Appropriateness of transfusion of red cells, platelets and fresh frozen plasma; an audit in a tertiary care teaching hospital. Med J Aust. 1995;162(11): Muller M, de Jonge E, Sesmu Arbous M, et al. Transfusion of fresh frozen plasma in non bleeding ICU patients TOPIC TRIAL: study protocol for a randomized controlled trial. Trials. 2011;12: Vlaar A, Binnekade J, Prins D, Schultz MJ, Juffermans NP. A survey of physicians reasons to transfuse plasma and platelet in the critically ill: a prospective single-center cohort study. Transfus Med. 2009;19(4): Waston D, Stanworth S, Wyncoll D, et al. A National clinical scenario-based survey of clinicians attitudes towards fresh frozen plasma transfusion for critically ill patients. Transfus Med. 2011; 21(2): Peacock WF, Gearhart MM, Mills RM. Reviews emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol. 2012;35(12): Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarinassociated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc. 2007;82(1): Hall AB, Carson BC. Reversal of warfarin-induced coagulopathy: review of treatment options. Emerg Nurs. 2012;38(1): Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trails. Br J Haematol. 2004; 126(1): Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex in reversing warfarin anticoagulation; a review of the literature. Am J Hematol. 2008;83(2):
7 Only et al Goldstein JN, Thomas SH, Frotiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006;37(1): Makris M, van Veen JJ, Maclean R, Warfarin anticoagulation reversal; management of the asymptomatic and bleeding patient. J Thromb Thrombolysis. 2010;29(2): Patel IJ, Davidson JC, Nikolic B, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions (standards of practice). J Vasc Interv Radiol. 2012;23(6): Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion. The effect of plasma transfusion on coagulation test results. Am J Clin Pathol. 2006;126(1):
New Advances in Transfusion EM I LY CO BERLY, M D
New Advances in Transfusion EM I LY CO BERLY, M D TRANSFUSI ON M EDI CI NE FELLO W VANDERBI LT UNI VERSITY Objectives To discuss the terminology, components, transfusion risks, and dosing guidelines for
More informationVitamin K antagonist (VKA) therapy is routinely
International Normalized Ratio Versus Plasma Levels of Coagulation Factors in Patients on Vitamin K Antagonist Therapy Gene Gulati, PhD; Megan Hevelow, MS; Melissa George, DO; Eric Behling, MD; Jamie Siegel,
More informationWARFARIN REVERSAL GUIDELINE
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationWhen should I transfuse platelets and plasma for children? Dr Liz Chalmers. Consultant Paediatric Haematologist Royal Hospital for Children Glasgow
When should I transfuse platelets and plasma for children? Dr Liz Chalmers Consultant Paediatric Haematologist Royal Hospital for Children Glasgow When should I transfuse platelets and plasma in children?
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationJohn Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne
John Davidson Consultant in Intensive Care Medicine Freeman Hospital, Newcastle upon Tyne Overview of coagulation Testing coagulation Coagulopathy in ICU Incidence Causes Evaluation Management Coagulation
More informationTRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.
More informationMajor Haemorrhage Protocol. Commentary
Hairmyres Hospital Monklands Hospital Wishaw General Hospital Major Haemorrhage Protocol Commentary N.B. There is a separate NHSL protocol for the Management of Obstetric Haemorrhage Authors Dr Tracey
More informationHow Good is your INR? The Use of Certified Plasmas in PT/INR Testing. INR System. How Good is your INR? Outline
How Good is your INR? The Use of Certified Plasmas in PT/INR Testing Dot Adcock, MD Esoterix Coagulation Mayo/NASCOLA Coagulation Testing Quality Conference April 25, 2007 How Good is your INR? The Use
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Appropriate and Inappropriate Use of Fresh Frozen Plasma (FFP) and Packed Cell Volume (PCV)
More informationCAP Laboratory Improvement Programs. Appropriateness of Plasma Transfusion
CAP Laboratory Improvement Programs Appropriateness of Plasma Transfusion A College of American Pathologists Q-Probes Study of Guidelines, Waste, and Serious Adverse Events Kirsten Alcorn, MD; Glenn Ramsey,
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationPREDLOG SMERNIC ZA KLINIČNO UPORABE SVEŽE ZMRZNJENE PLAZME Guidelines for clinical use of FFP proposal
PREDLOG SMERNIC ZA KLINIČNO UPORABE SVEŽE ZMRZNJENE PLAZME Guidelines for clinical use of FFP proposal Dragoslav Domanovič, MD. PhD. Blood transfusion centre of Slovenia, Ljubljana FFP - definition Fresh
More informationStability of prothrombin time and activated partial thromboplastin time tests under different storage conditions
Clinica Chimica Acta 300 (2000) 13 21 www.elsevier.com/ locate/ clinchim Stability of prothrombin time and activated partial thromboplastin time tests under different storage conditions L.V. Rao *, A.O.
More informationGuidelines for the management of warfarin reversal in adults
SharePoint Location Clinical Policies and Guidelines SharePoint Index Directory General Policies and Guidelines Sub Area Haematology and Transfusion Key words (for search purposes) Warfarin, Bleeding Central
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationTransfusion Requirements and Management in Trauma RACHEL JACK
Transfusion Requirements and Management in Trauma RACHEL JACK Overview Haemostatic resuscitation Massive Transfusion Protocol Overview of NBA research guidelines Haemostatic resuscitation Permissive hypotension
More informationHuman Prothrombin Complex (PCC) (Beriplex P/N) in the emergency reversal of anticoagulation BCSLS Congress 2012 Kamloops, BC
Human Prothrombin Complex (PCC) (Beriplex P/N) in the emergency reversal of anticoagulation BCSLS Congress 2012 Kamloops, BC Ayman Kafal Medical Affairs, Leader CSL Behring Canada 1 Prothrombin Complex
More informationNICE guideline Published: 18 November 2015 nice.org.uk/guidance/ng24
Blood transfusion NICE guideline Published: 18 November 2015 nice.org.uk/guidance/ng24 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. octaplaslg mg/ml solution for infusion Human plasma proteins
PACKAGE LEAFLET: INFORMATION FOR THE USER octaplaslg 45-70 mg/ml solution for infusion Human plasma proteins Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet.
More informationMANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY
MANAGEMENT OF COAGULOPATHY AFTER TRAUMA OR MAJOR SURGERY 19th ANNUAL CONTROVERSIES AND PROBLEMS IN SURGERY Thabo Mothabeng General Surgery: 1 Military Hospital HH Stone et al. Ann Surg. May 1983; 197(5):
More informationBlood Transfusion Guidelines in Clinical Practice
Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi
More informationHemostasis and thrombosis in patients with liver disease. Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands
Hemostasis and thrombosis in patients with liver disease Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands Importance of the liver in hemostasis Synthesis of Coagulation factors Fibrinolytic proteins
More informationCrossmatching and Issuing Blood Components; Indications and Effects.
Crossmatching and Issuing Blood Components; Indications and Effects. Alison Muir Blood Transfusion, Blood Sciences, Newcastle Trust Topics Covered Taking the blood sample ABO Group Antibody Screening Compatibility
More informationCoagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU
Coagulation Disorders Dr. Muhammad Shamim Assistant Professor, BMU 1 Introduction Local Vs. General Hematoma & Joint bleed Coagulation Skin/Mucosal Petechiae & Purpura PLT wound / surgical bleeding Immediate
More informationTRAUMA RESUSCITATION. Dr. Carlos Palisi Dr. Nicholas Smith Liverpool Hospital
TRAUMA RESUSCITATION Dr. Carlos Palisi Dr. Nicholas Smith Liverpool Hospital First Principles.ATLS/EMST A- Airway and C-spine B- Breathing C- Circulation and Access D- Neurological deficit E- adequate
More informationActive date July Ratification date: Review date January 2014 Applies to: Staff managing patients on warfarin. Exclusions:
Guideline Title: Guidelines for the management of warfarin reversal [key words : Beriplex, Octaplex, PCC, vitamin K, anticoagulant, anticoagulation] Authors: Dr Sarah Allford, Consultant Haematologist
More informationTRANSFUSIONS FIRST, DO NO HARM
TRANSFUSIONS FIRST, DO NO HARM BECAUSE BLOOD CAN KILL 7 TRALI DEATHS SINCE 2002 WMC 5 women BECAUSE In OB you are transfusing 2 instead of 1 BECAUSE BLOOD IS A LIQUID TRANSPLANT RISKS versus BENEFITS versus
More informationManaging Coagulopathy in Intensive Care Setting
Managing Coagulopathy in Intensive Care Setting Dr Rock LEUNG Associate Consultant Division of Haematology, Department of Pathology & Clinical Biochemistry Queen Mary Hospital Normal Haemostasis Primary
More informationEMSS17: Bleeding patients course material
EMSS17: Bleeding patients course material Introduction During the bleeding patients workshop at the Emergency Medicine Summer School 2017 (EMSS17) you will learn how to assess and treat bleeding patients
More informationP re-analytical conditions are very important in laboratory assessment of hemostatic and coagulation systems
OPEN SUBJECT AREAS: PRE-CLINICAL STUDIES PROTEASES BIOCHEMICAL ASSAYS BIOPHYSICAL CHEMISTRY Received 19 November 2013 Accepted 8 January 2014 Published 27 January 2014 Correspondence and requests for materials
More informationCitation for published version (APA): Müller, M. C. A. (2014). Coagulopathy and plasma transfusion in critically ill patients
UvA-DARE (Digital Academic Repository) Coagulopathy and plasma transfusion in critically ill patients Müller, Marcella Link to publication Citation for published version (APA): Müller, M. C. A. (2014).
More informationRoutine preoperative coagulation tests: are they necessary?
Routine preoperative coagulation tests: are they necessary? Dr Azzah Alzahrani MD Pediatrics Hematology /Oncology PSMMS Outline Introduction. Brief review of hemostatic mechanisms. A clinical aspect of
More informationHematology Review. CCRN exam. The Coagulation Cascade. The Coagulation Cascade. Components include: Intrinsic pathway Extrinsic pathway Common pathway
CCRN exam Hematology Review CCRN Review October 2013 Department of Critical Care Nursing Hematology is 2% of the exam Focus on coagulation cascade, DIC, and HIT Anatomy of the hematologic system Bone marrow
More informationTransfusion strategies in patients with cirrhosis: less is more. 1. Department of Gastroenterology, Hillingdon Hospital, London, UK
Transfusion strategies in patients with cirrhosis: less is more Evangelia M. Fatourou 1, Emmanuel A. Tsochatzis 2 1. Department of Gastroenterology, Hillingdon Hospital, London, UK 2. UCL Institute for
More informationRecombinant factor VIIa: Hype or hope? Jed Gorlin MD, MBA
Recombinant factor VIIa: Hype or hope? Jed Gorlin MD, MBA Goals of presentation Challenge current use of rviia using data Review how rviia works Approved indications Review results of randomized trials
More informationBlood transfusion. Dr. J. Potgieter Dept. of Haematology NHLS - TAD
Blood transfusion Dr. J. Potgieter Dept. of Haematology NHLS - TAD General Blood is collected from volunteer donors >90% is separated into individual components and plasma Donors should be: healthy, have
More informationMASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE
MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE CONTENTS Definition Indications Transfusion trigger Massive transfusion protocol Complications DEFINITION Massive transfusion:
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationCoagulation, Haemostasis and interpretation of Coagulation tests
Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect
More informationGuideline for Treatment of Head Injury in the Anticoagulated Patient
Guideline for Treatment of Head Injury in the Anticoagulated Patient GUIDELINE: GUIDELINE FOR TREATMENT OF HEAD INJURY IN THE ANTICOAGULATED PATIENT BACKGROUND: Chronic anticoagulation therapy is used
More informationA Look at Patient Compliance to INR Testing and Therapeutic Range Management of Patients on Warfarin at Agassiz Medical Center.
A Look at Patient Compliance to INR Testing and Therapeutic Range Management of Patients on Warfarin at Agassiz Medical Center Lauren Martens Abstract This study sought to determine the total number of
More informationEvaluation Report. Eurolyser PT (INR) test kit (ST0180) on CUBE and smart analysers
Evaluation Report Eurolyser PT test kit (ST0180) on CUBE and smart analysers Locations Location 1: Eurolyser Diagnostica GmbH Operator: Simone Wieser Date: 30.06.2015 Specimens The specimens used for analysis
More informationUse of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference
Use of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference John A. Aucar, MD, MSHI, FACS, CPE EmCare Acute Care Surgery Del Sol Medical Center Associate Professor, University
More informationthe bleeding won t stop? Liane Manz RN, BScN, CNCC(c) Royal Alexandra Hospital
What do you do when the bleeding won t stop? Teddie Tanguay RN, MN, NP, CNCC(c) Teddie Tanguay RN, MN, NP, CNCC(c) Liane Manz RN, BScN, CNCC(c) Royal Alexandra Hospital Outline Case study Normal coagulation
More informationGUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN
GUIDELINES FOR MANAGEMENT OF OVER ANTICOAGULATION WITH WARFARIN Version Date Purpose of Issue/Description of Change Review Date 1 29/11/05 New Policy December 2007 2 Oct 07 Review Oct 09 3 March 10 Review
More informationEvaluation of the Precision and Accuracy of the INRatio 2 Prothrombin Time (PT) Monitoring System
Evaluation of the Precision and Accuracy of the INRatio 2 Prothrombin Time (PT) Monitoring System Grace DeSantis, PhD Lisa Croner, PhD Michealle Havenhill, BA Shari Kipp, BSc (Honours) MBA Inverness Medical,
More informationGuidelines for Use of Canine Blood Components
Guidelines for Use of Canine Blood Components Cryoprecipitate This product is prepared by a controlled thaw of fresh frozen plasma, resulting in a concentration of Factor VIII, Factor XIII, vwf and some
More informationShock and Resuscitation: Part II. Patrick M Reilly MD FACS Professor of Surgery
Shock and Resuscitation: Part II Patrick M Reilly MD FACS Professor of Surgery Trauma Patient 1823 / 18 Police Dropoff Torso GSW Lower Midline / Right Buttock Shock This Monday Trauma Patient 1823 / 18
More informationEDUCATIONAL COMMENTARY ORAL ANTICOAGULANT THERAPEUTIC MONITORING AND POINT-OF-CARE TESTING
POINT-OF-CARE TESTING Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Continuing Education on
More information6 semanas de embarazo. Critical pt inr levels. Inicio / Embarazo / 6 semanas de embarazo
Inicio / Embarazo / 6 semanas de embarazo 6 semanas de embarazo Critical pt inr levels INR is the result of the patient PT/mean normal PT, exponentially equalized by the ISI. INR levels above 4.9 are considered
More informationHEME 10 Bleeding Disorders
HEME 10 Bleeding Disorders When injury occurs, three mechanisms occur Blood vessels Primary hemostasis Secondary hemostasis Diseases of the blood vessels Platelet disorders Thrombocytopenia Functional
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationOral Factor Xa Inhibitors and Clinical Laboratory Monitoring
Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationWhat s in the Massive Transfusion Protocol (MTP) Package?
What s in the Massive Transfusion Protocol (MTP) Package? The Massive Transfusion Protocol Package is a set of documents intended to improve the coordination of a Massive Transfusion Protocol. The kit
More informationUse of Prothrombin Complex Concentrates (PCC) CONTENTS
CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis
More informationSign up to receive ATOTW weekly -
ANTICOAGULATION & INTRACRANIAL BLEEDS - MANAGEMENT OF THE ANTICOAGULATED PATIENT PRESENTING WITH INTRACRANIAL HAEMORRHAGE ANAESTHESIA TUTORIAL OF THE WEEK 82 12 th January 2008 Rebecca Appelboam, Exeter,
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationAgent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min
Nanik (Nayri) Hatsakorzian Pharm.D/MPH candidate 2014 Touro University College of Pharmacy CA Bleeding Reversal Agents Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes
More informationAnatomy and Physiology
Anatomy and Physiology For The First Class 2 nd Semester Thrombocytes = Platelets Thrombocytes = Platelets Blood platelets are non-nucleated disc like cell fragments 2-4 µm in diameter. Platelets are not
More information2/2/2011. Blood Components and Transfusions. Why Blood Transfusion?
Blood Components and Transfusions Describe blood components Identify nursing responsibilities r/t blood transfusion Discuss factors r/t blood transfusion including blood typing, Rh factor, and cross matching
More informationBLEEDING DISORDERS Simple complement:
BLEEDING DISORDERS Simple complement: 1. Select the statement that describe the thrombocytopenia definition: A. Marked decrease of the Von Willebrandt factor B. Absence of antihemophilic factor A C. Disorder
More information4/23/2009. September 15, 2008
The Current Treatment of Deep Venous Thrombosis: Are We Doing Enough? George H. Meier, MD Professor and Chief Division of Vascular Surgery University of Cincinnati College of Medicine Cincinnati, Ohio
More informationHow can ROTEM testing help you in cardiac surgery?
How can ROTEM testing help you in cardiac surgery? Complicated bleeding situations can appear intra and post operatively. They can be life-threatening and always require immediate action. A fast differential
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More informationImprovement in Intraoperative Fresh Frozen Plasma Transfusion Practice -Impact of Medical Audits and Provider Education
Improvement in Intraoperative Fresh Frozen Plasma Transfusion Practice -Impact of Medical Audits and Provider Education Hameedullah,F.A.Khan,R.S.Kamal ( Department of Anaesthesia, The Aga Khan University
More informationThyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A.
UvA-DARE (Digital Academic Repository) Thyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A. Link to publication Citation for published version (APA): Squizzato, A.
More informationThe LaboratoryMatters
Laboratory Medicine Newsletter for clinicians, pathologists & clinical laboratory technologists. A Initiative. HEMOSTASIS AND THE LABORATORY This issue highlights: Primary Hemostasis Screening Tests Case
More informationFIGURE 1. Coagulation cascade. a = activated factor; Ca = calcium; PL = phospholipid. Adapted from Biochemistry, 2 with permission from American Chemi
CONCISE REVIEW FOR CLINICIANS PROLONGED PT AND APTT How to Interpret and Pursue an Abnormal Prothrombin Time, Activated Partial Thromboplastin Time, and Bleeding Time in Adults ARIF H. KAMAL, MD; AYALEW
More informationUniversity of Groningen. Blood platelets in liver transplantation Pereboom, Ilona Tapke Annie
University of Groningen Blood platelets in liver transplantation Pereboom, Ilona Tapke Annie IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationHemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins
Hemostasis Learning objectives 14-16 Dr. Mária Dux Components: blood vessel wall thrombocytes (platelets) plasma proteins Hemostatic balance! procoagulating activity anticoagulating activity 1 Thrombocytes
More informationPrimary Exam Physiology lecture 5. Haemostasis
Primary Exam Physiology lecture 5 Haemostasis Haemostasis Body s response for the prevention and cessation of bleeding. Broadly consists of: Primary Haemostasis - vascular spasm and platlet plug formation
More informationDo children without a known bleeding tendency undergoing PICC placement require coagulation laboratory testing?
Pediatr Radiol (2015) 45:727 735 DOI 10.1007/s00247-014-3207-6 ORIGINAL ARTICLE Do children without a known bleeding tendency undergoing PICC placement require coagulation laboratory testing? Joel Woodley-Cook
More informationCoagulopathy: Measuring and Management. Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine
Coagulopathy: Measuring and Management Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine No Financial Disclosures Objectives Define coagulopathy of trauma Define
More informationEffects of preanalytical frozen storage time and temperature on screening coagulation tests and factors VIII and IX activity
www.nature.com/scientificreports Received: 8 February 2017 Accepted: 30 August 2017 Published: xx xx xxxx OPEN Effects of preanalytical frozen storage time and temperature on screening coagulation tests
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationGUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS
GUIDELINES FOR MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION WITH ORAL ANTICOAGULANTS This guideline covers the management of patients being treated with Vitamin K antagonists (VKA): Warfarin Acenocoumarol
More informationMassive Transfusion. MPQC Spring Summit April 29, Roger Belizaire MD PhD
Massive Transfusion MPQC Spring Summit April 29, 2015 Roger Belizaire MD PhD Take home points 1. Blood is always available. Requests for massive transfusion or emergency release typically only require
More informationWhat are blood clots?
What are blood clots? Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner Westcliffe Medical Group Created 5/31/18 Dr. Matthew
More informationPatient Blood Management: At the Forefront of Quality and Value in Healthcare
Patient Blood Management: At the Forefront of Quality and Value in Healthcare Ryan A. Metcalf, MD, CQA(ASQ) Associate Medical Director, University Hospital Transfusion Services and ARUP Blood Services
More informationBlood Product Utilization A Mythbusters! Style Review. Amanda Haynes, DO 4/28/18
Blood Product Utilization A Mythbusters! Style Review Amanda Haynes, DO 4/28/18 Objectives Describe concepts in Patient Blood Management Review common misconceptions surrounding blood transfusion Summarize
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationBlood is serious business
Transfusion at RCH BLOOD TRANSFUSION Anthea Greenway Dept of Clinical Haematology >10000 fresh blood products per year Supports craniofacial and cardiac surgery Support bone marrow, liver transplant and
More informationClinical Implications of the Impact of Serum Tissue Factor Levels after Trauma
Clinical Implications of the Impact of Serum Tissue Factor Levels after Trauma Ian E. Brown, MD, PhD, and Joseph M. Galante MD, FACS Formatted: Font: 16 pt, Bold Formatted: Centered Formatted: Font: Bold
More informationKcentra Formulary Kit
Formulary Kit The first and only 4F-PCC for urgent warfarin reversal Important Safety Information is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationPre-hospital Administration of Blood Products (PHBP) and Tranexamic acid (TXA): Is the Jury Still Out?
Pre-hospital Administration of Blood Products (PHBP) and Tranexamic acid (TXA): Is the Jury Still Out? Jessica K. Reynolds, MD Assistant Professor of Surgery University of Kentucky, Department of Trauma
More informationApproach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate
Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:
More informationDetermination of APTT factor sensitivity the misguiding guideline
International Journal of Laboratory Hematology ORIGINAL ARTICLE The Official journal of the International Society for Laboratory Hematology INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY Determination
More informationTitle of Guideline (must include the word Guideline (not protocol, policy, procedure etc)
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Guideline on the management of excessive coumarin anticoagulation in adults
More informationIntraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL
Intraoperative haemorrhage and haemostasis Dr. med. Christian Quadri Capoclinica Anestesia, ORL Haemostasis is like love. Everybody talks about it, nobody understands it. JH Levy 2000 Intraoperative Haemorrhage
More informationUNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.
UNIT VI Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav Hemostasis: Prevention of Blood Loss Vascular constriction Formation of a platelet plug Formation of a blood
More informationBlood Component Therapy
Blood Component Therapy Dr Anupam Chhabra Incharge-Transfusion Medicine Pushpanjali Crosslay Hopital NCR-Delhi Introduction Blood a blood components are considered drugs because of their use in treating
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationPlasma therapy : indications &
Plasma therapy : indications & recommendations in France F. HESHMATI 3rd International congress of Transfusion Medicine Iran, Tehran Available types of therapeutic plasma In France, EU & USA Cll Collection
More informationDeep venous thrombosis and pulmonary embolism in joint replacement surgery
Deep venous thrombosis and pulmonary embolism in joint replacement surgery Even though joint replacement surgery is an effective procedure and in expert hands yields a low complication rate, deep venous
More information